TriFlo Cardiovascular
About:
TriFlo Cardiovascular focuses on minimally invasive transcatheter solutions to treat tricuspid valve regurgitation.
Website: https://triflocv.com/
Description:
TriFlo Cardiovascular is a biotechnology company that focuses on minimally invasive transcatheter solutions to treat tricuspid valve regurgitation.
Total Funding Amount:
$14.7M
Headquarters Location:
Huntington Beach, California, United States
Founded Date:
2017-01-01
Founders:
Luca Pesce
Number of Employees:
1-10
Last Funding Date:
2021-12-22
IPO Status:
Private
Industries:
© 2025 bioDAO.ai